Authors


Andrew M. Wood, MD

Latest:

iRARC adoption is slow but persistent in bladder cancer

"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.


Andrew Radtke, MD

Latest:

Going “retro”: A perspective on robotic retroperitoneal renal surgery

Improvements in technology have renewed interest in the technique.


Stephen A. Boorjian, MD

Latest:

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.


Caroline Seymour

Latest:

Dr. Xu discusses treatment selection across therapy lines in renal cell carcinoma

“Now in 2023, it’s really a question of how to apply these agents and which combinations to use in the first line,” said Vincent (Wenxin) Xu, MD.


Janelle Hart

Latest:

Asked by a Resident: Dr. Efe Chantal Ghanney Simons interviews Dr. Mark S. Litwin

"The most important thing I feel I've learned in my life so far is the value of human interaction and human connection," says Mark S. Litwin, MD, MPH.



Brian Helfand, MD, PhD

Latest:

Future Directions in Imaging for Patients With Prostate Cancer

Closing out his review of imaging modalities in the setting of prostate cancer, Brian Helfand, MD, PhD, looks toward future evolutions in detection and treatment.


Kathleen M. Olson, MD

Latest:

Urologic implications of Lynch syndrome

Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.


Rachelle Manookian, MS, CGC

Latest:

What is genetic discrimination, and why does it matter?

Fear of discrimination has downstream effects on health care.



Amanda Hill, JD

Latest:

Strategies for dealing with difficult patients

In this article, an expert addresses the most common issues that come up with patients that may make them harder to deal with and solutions that may help a provider.


Rainjade Chung, MD

Latest:

Management of hormone-naïve oligometastatic prostate cancer

Growing evidence supports the existence of an intermediate metastatic disease state.


Steven P. Mathew, PharmD

Latest:

Drug interactions to monitor when prescribing erectile dysfunction medications

Many of the medications used in the treatment of ED have interactions with other medications, so it is crucial to carefully examine patient profiles to optimize therapy and ensure safety.


Michigan Institute of Urology

Latest:

Michigan Institute of Urology (MIU) joins Solaris Health, nation's largest urological services provider

MIU seizes innovation opportunities presented by dynamic national urology platform caring for nearly one-half million patients.


Tarik Benidir, MD

Latest:

The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy

"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.


Mark D. Tyson, MD, MPH

Latest:

Urologic implications of Lynch syndrome

Research indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.


Northwestern Medicine

Latest:

Improving immune responses in prostate cancer

Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery.


Matthew Fowler

Latest:

Encouraging antitumor activity seen with neoadjuvant enfortumab vedotin in patients with cisplatin-ineligible MIBC

“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.


Courtney Marabella

Latest:

Update offers clues to optimal olaparib use in prostate cancer

The latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.


Logan Lutton

Latest:

Coaching program aims to alleviate female physician burnout

Cofounders Adrienne Mann, MD, and Tyra Fainstad, MD, discuss Better Together, a professional, structured coaching program designed to address the burnout experienced by women in medicine.


American Urogynecologic Society

Latest:

Get eTOC alerts from Urogynecology

Subscribe to get new issue email alerts for Urogynecology that include the table of contents for the publication.


Darlene Dobkowski, MA

Latest:

Tumor mutation burden may predict outcomes from ADC in urothelial carcinoma

The ORR for patients was 47%. Of note, ORRs were higher in patients with specific alterations compared with wild type including ERBB2 (67% vs. 44%, respectively; P = .05) and TSC1 (68% vs. 25%; P = .04).


Kelvin Moses, MD, PhD

Latest:

Diversity in Urology: Progress made, but there is more work to be done

Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.


Renee Dowling

Latest:

Everything you need to know about medical coding and billing audits

Through medical claims audits, the practice can help protected itself against fraudulent billing activity and claims.


Lauren Hanson

Latest:

Tips for physicians to improve work-life balance

Overworking has become the norm, but that doesn’t mean it should be.


Pharmacy Times Staff

Latest:

Case report details spontaneous bladder rupture caused by herpes zoster–associated urinary retention

Although cases of acute urinary retention and defecation caused by herpes zoster in the sacral area have been reported, no clinical cases about spontaneous bladder rupture have been previously published, according to the authors.


Jim Lu, MD, PhD

Latest:

Molecular diagnostic practice in prostate and bladder cancers

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.


Daniel A. Barocas, MD, MPH, FACS

Latest:

Strategies to mitigate impact of intravenous ICM shortage

"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.


Dave S. Gilreath, CFP

Latest:

Money Matters: Informing your perspective on the bear market

No matter what your age or risk tolerance, investing is a lot easier and likely more successful if your perspective is informed by market history.


Shane Peng, MD

Latest:

Expert explains challenges of telehealth

Although much of the discourse around telehealth rightfully focuses on its benefits, the potential drawbacks and limitations are often glossed over, particularly around provider burden.

© 2023 MJH Life Sciences

All rights reserved.